C. H. Robinson Worldwide vs RXO
CHRW and RXO side by side, both in transportation services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CHRW and RXO compare
C. H. Robinson Worldwide is the larger company, worth 3.3 times as much as RXO ($15.6B against $4.7B).
C. H. Robinson Worldwide grew revenue faster over the last twelve months (10.4% versus 10.1% for RXO).
C. H. Robinson Worldwide keeps more of each dollar of sales as profit, with a net margin of 3.7% compared with −1.3% at RXO.
C. H. Robinson Worldwide pays a dividend yielding 1.9%; RXO does not pay one.
C. H. Robinson Worldwide scores higher on the StockData Score (16 against 4 for RXO), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRW | RXO |
|---|---|---|
| Size and price | ||
| Market cap | $15.6B | $4.7B |
| Share price | $134.46 | $28.42 |
| Change, 1 year | −12.1% | 130% |
| Change, 5 years | 39.7% | – |
| Beta (5Y) | 0.70 | 1.71 |
| Employees | 12K | 9,218 |
| StockData Score | ||
| Total score | 16 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 6 (better) | 0 |
| Health score | 3 | 3 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 24.1× | – |
| P/S | 0.9× | 0.7× (better) |
| P/B | 9.9× | 3.1× (better) |
| EV/EBITDA | 17.6× (better) | 92.1× |
| P/FCF | 30.0× | – |
| FCF yield | 3.3% (better) | −1.6% |
| Fair value | $108.48 | $9.41 |
| Margin of safety | −24.0% (better) | −202% |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 10.1% |
| Revenue growth, 5Y average | 0.03% | 11.3% (better) |
| Net income growth (TTM) | 11.5% | – |
| EPS growth (TTM) | 13.0% | – |
| EPS growth, 5Y average | 5.4% | – |
| Profitability | ||
| Gross margin | – | 17.7% |
| Operating margin | 4.9% (better) | −0.80% |
| Net margin | 3.7% (better) | −1.3% |
| FCF margin | 2.9% (better) | −1.1% |
| Return on equity | 38.9% (better) | −5.7% |
| Return on invested capital | 23.4% (better) | −2.1% |
| Financial health | ||
| Debt / equity | 1.18 | 0.33 (better) |
| Net debt / EBITDA | 1.71 (better) | 8.41 |
| Current ratio | 1.34 (better) | 1.28 |
| Altman Z-score | 6.85 (better) | 3.19 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | – |
| Payout ratio | 45.4% | – |
| Years of dividend growth | 16 | – |
| Dividend growth, 5Y average | 4.1% | – |
| Buyback yield | 4.8% | – |
| Shareholder yield | 6.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 107% | 110% |
| Held by insiders | 0.73% | 22.1% |
| Insider net buying, 12 months | −$3.7M | $6.4M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.7% | 6.1% |
Go deeper
- CHRW stock overview
- CHRW income statement
- CHRW valuation and score
- RXO stock overview
- RXO income statement
- RXO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.